Current advances in tumor proteomics and candidate biomarkers for hepatic cancer.
Tumor proteomics apply proteomics techniques to tumor biological research, mainly by screening candidate biomarkers for early tumor diagnosis, prognosis and treatment. Hepatocellular carcinoma (HCC) is a type of malignant tumor with one of the highest death rates in the world. With the advent of the post-genomic age, tumor biological research developing the technology of proteomics has become a major focus of researchers. The discovery of novel candidate biomarkers is one of crucial problems for the early diagnosis of HCC. In general, there are three distinct types of candidate biomarkers for HCC based on different areas: biochemical biomarkers, antigenic biomarkers and epigenetic biomarkers. This review mainly discusses current advances in the problems and prospects of candidate biomarker for the early diagnosis of HCC, discovered by technologies of tumor proteomics.
Peng
Xin-Qing
XQ
Department of Biotechnology, Gui-Lin Medical University, 541004 China.
Wang
Fei
F
Geng
Xin
X
Zhang
Wei-Ming
WM
D014408:Biomarkers, Tumor / Q000378:metabolism; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000378:metabolism*; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000378:metabolism*; D040901:Proteomics
D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins